Quick Summary:
In the ever-growing sphere of neurodegenerative research, the comprehensive analysis offered in our market research report is a critical asset for any serious industry player. The global market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases, currently valued at $7.5 Billion, promises lucrative growth opportunities, with a projection to reach $14.7 Billion by 2030.
Keep your organisation on top of major market trends and dynamics with insights into significant geographic markets such as the US and China that hold considerable potential. The report provides in-depth competitor profiles of key industry players including Abbott Laboratories, Bio-Rad Laboratories and Thermo Fisher Scientific. Benefit from a special coverage on market presence across multiple geographies and online interactive peer-to-peer collaborative bespoke updates. Inclusion of complimentary updates for one year ensures your business stays aligned with the industry pulse in this evolving sector.
Global Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases Market to Reach $14.7 Billion by 2030
The global market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases estimated at US$7.5 Billion in the year 2022, is projected to reach a revised size of US$14.7 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2022-2030.
The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 8.3% CAGR
The Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases market in the U.S. is estimated at US$2.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 7.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.Select Competitors (Total 46 Featured) -
- AbaStar MDx
- Abbott Laboratories
- Abiant
- Acumen Pharmaceuticals
- Alseres Pharmaceuticals
- Athena Diagnostics
- Athena Diagnostics
- Banyan Biomarkers
- Bio-Rad Laboratories
- Diagenic ASA
- Immunarray Pvt. Ltd.
- Myriad RBM
- Proteome Sciences
- ProteoSys AG
- Psynova Neurotech
- Qiagen
- Quanterix Corporation
- Thermo Fisher Scientific
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases?
What is the growth rate of the Global Market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases?
What is the forecasted size of the Global Market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases?
Who are the key companies in the Global Market for Neurological Biomarkers for Alzheimer`s and Parkinson`s Diseases?
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | November 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 7.5 Billion |
| Forecasted Market Value ( USD | $ 14.7 Billion |
| Compound Annual Growth Rate | 8.8% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbaStar MDx
- Abbott Laboratories
- Abiant
- Acumen Pharmaceuticals
- Alseres Pharmaceuticals
- Athena Diagnostics
- Athena Diagnostics
- Banyan Biomarkers
- Bio-Rad Laboratories
- Diagenic ASA
- Immunarray Pvt. Ltd.
- Myriad RBM
- Proteome Sciences
- ProteoSys AG
- Psynova Neurotech
- Qiagen
- Quanterix Corporation
- Thermo Fisher Scientific
